Pharmacovigilance of herbal medicines: A UK perspective

Drug Safety

Volumn 26, Issue 12, 2003, Pages 829-851

  Barnes, Joanne ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICA ARCHANGELICA EXTRACT; ARISTOLOCHIC ACID; ECHINACEA ANGUSTIFOLIA EXTRACT; ECHINACEA PALLIDA EXTRACT; ECHINACEA PURPUREA EXTRACT; FUROCOUMARIN; GINKGO BILOBA EXTRACT; HYPERICUM PERFORATUM EXTRACT; KAVA; PLANT MEDICINAL PRODUCT; SENECIONINE; UNCLASSIFIED DRUG;

ANGELICA; ANGELICA ARCHANGELICA; COMMUNITY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; ECHINACEA ANGUSTIFOLIA; ECHINACEA PALLIDA; ECHINACEA PURPUREA; EVALUATION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; LIVER TOXICITY; MEDICAL PERSONNEL; MEDICAL RECORD; MEDICINAL PLANT; MONITORING; NEPHROTOXICITY; PHARMACIST; PHARMACOGENETICS; PHARMACOGENOMICS; PHOTOTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

GREAT BRITAIN; HUMANS; MEDICINE, HERBAL; PHARMACEUTICAL SERVICES; PLANT PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0141839144     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326120-00001     Document Type: Review

References (81)

1. Mann RD, Andrews EB, editors. Pharmacovigilance. Chicester: Wiley, 2002
2. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17-29
3. World Health Organization. Draft WHO guidelines on safety monitoring and pharmacovigilance of herbal medicines. Geneva: World Health Organization, 2003
4. European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on quality of herbal medicinal products. CPMP/QWP/2819/00 (EMEA/CVMP/814/00). London: EMEA, July 26, 2001 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/qwp/281900en.pdf [Accessed 2003 Aug 13]
5. The Medicines Act. London: The Stationery Office, 1968
6. Commission of the European Communities. Proposal for amending the directive 2001/83/EC as regards traditional herbal medicinal products. 2002/ 0008 (COD). Brussels: European Commission, 2002
7. Commission of the European Communities. Amended proposal for a Directive of the European Parliament and of the Council amending the directive 2001/83/EC as regards traditional herbal medicinal products. 2002/0008 (COD). Brussels: European Commission, 2003
8. Barnes J, Anderson LA, Phillipson JD. Herbal medicines: a guide for healthcare professionals. London: Pharmaceutical Press, 2002
9. De Los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St John's wort. Am J Health Syst Pharm 2002; 59: 545-7
10. Kressman S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002; 54: 661-9
11. Loew D, Kaszkin M. Approaching the problem of bioequivalence of herbal medicinal products. Phytother Res 2002; 16: 705-11
12. Woodfield R. Senecio species in unlicensed herbal remedies [letter]. London: Medicines Control Agency, 2002
13. Medicines and healthcare products Regulatory Agency. Herbal safety news [online]. Available from URL: http://medicines.mhra.gov.uk [Accessed 2003 Jul 29]
14. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 2001; 9: 2-11
15. Mintel International Group Ltd. Complementary medicines, UK. April 2003. London: Mintel International Group Limited, 2003
16. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a national follow-up survey. JAMA 1998; 280 (18): 1569-75
17. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 166-73
18. Barnes J. Herbal therapeutics (1): an introduction to herbal medicinal products. Pharm J 2002; 268: 804-6
19. Barnes J, Ernst E. Traditional herbalists' prescriptions for common clinical conditions: a survey of members of the UK National Institute of Medical Herbalists. Phytother Res 1999; 12: 369-71
20. Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496-500
21. Gulian C, Barnes J, Francis S-A. Types and preferred sources of information concerning herbal medicinal products: face-to-face interviews with users of herbal medicinal products [abstract]. Int J Pharm Prac 2002; 10 Suppl.: R33
22. Vickers AJ, Rees RW, Robin A. Advice given by health food stores: is it clinically safe? J R Coll Phys Lond 1998; 32 (5): 426-8
23. Quinn CG, Waterman P. A comparison of the teaching of herbal medicine in the United Kingdom and Europe. University of Strathclyde, 1997
24. Barnes J, Abbot NC. Experiences with complementary medicines: a survey of community pharmacists [abstract]. Pharm J 1999; 263: R37-43
25. Barnes J. An examination of the role of the pharmacist in the safe, effective and appropriate use of complementary medicines [PhD thesis]. University of London, 2001
26. Department of Health. Herbal Medicine Regulatory Working Group [online]. Available from URL: http://www.doh.gov.uk/herbalmedicinerwg [Accessed 2003 Jul 29]
27. Medicines Control Agency. Traditional ethnic medicines: public health and compliance with medicines law. November 2001. London: Medicines Control Agency, 2001
28. The Medicines (Aristolochia and Mu Tong) (Prohibition) Order 2001 (SI 2001/1841). London: The Stationery Office, 2001
29. Commission of the European Communities. Directive 2001/83/EC. Brussels: European Commission, 2001
30. Adcock H. Medicines Control Agency proposes ban for kava-containing products. Pharm J 2002; 269: 128
31. Royal Pharmaceutical Society of Great Britain. Medicines, ethics and practice: a guide for pharmacists. London: Royal Pharmaceutical Society of Great Britain, 2003 Jul: 92
32. De Smet PAGM, Hänsel R, Keller K, et al., editors. Toxicological outlook on quality assurance of herbal remedies. In: Adverse effects of herbal drugs. Vol 1. Berlin: Springer Verlag, 1992
33. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inf J 2000; 34: 15-23
34. Ernst E. De Smet PA, Shaw D, et al. Traditional remedies and the "test of time". Eur J Clin Pharmacol 1998; 54 (2): 99-100
35. De Smet PAGM. Health risks of herbal remedies. Drag Saf 1995; 13 (2): 81-93
36. Woodfield R. Proposed directive on traditional herbal medicinal products: progress in European negotiations [letter]. London: Medicines and Healthcare products Regulatory Agency, 2003
37. Press release (revised). Meeting of the Working Party on Herbal Medicinal Products. February 24-25, 2003, European Agency for the Evaluation of Medicinal Products, London. Document reference: EMEA/CPMP/HMPWP/1090/03Rev.1
38. De Smet PAGM. An introduction to herbal pharmacovigilance. In: De Smet PAGM, Keller K, Hänsel R, et al., editors. Adverse effects of herbal drugs. Vol. 3. Berlin: Springer-Verlag, 1997
39. Extension of the yellow card scheme to unlicensed herbal remedies. Curr Prob Pharmacovigilance 1996; 22: 10
40. Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997; 17 (5): 342-56
41. Extension of the yellow card scheme to pharmacists. Curr Prob Pharmacovigilance 1997; 23: 3
42. Davis S, Coulson R. Community pharmacist reporting of suspected ADRs: (1) the first year of the yellow card demonstration scheme. Pharm J 1999; 263: 786-8
43. Medicines and Healthcare Products Regulatory Agency. Adverse drug reaction on-line information tracking (ADROIT) system, Jul 25, 2003
44. Major E. The yellow card scheme and the role of pharmacists as reporters. Pharm J 2002; 269: 25-6
45. Davis S, Raine JM. Spontaneous reporting: UK. In: Mann RD, Andrews E, editors. Pharmacovigilance. Chicester: Wiley, 2002: 195-207
46. Committee on Safety of Medicines and Medicines and Healthcare Products Regulatory Agency. The yellow card scheme: extension of the yellow card scheme to nurse reporters [online]. Available from URL: http://medicines.mhra.gov.uk/aboutagency/regframework/csm/csmhome.htm [Accessed 2003 Jul 25]
47. MCA launches web version of yellow card scheme. Pharm J 2002; 269: 631
48. Patients able to report ADRs via NHS Direct. Pharm J 2003; 270: 608
49. Morrison-Griffiths S, Walley TJ, Park BK, et al. Reporting of adverse drug reactions by nurses. Lancet 2003; 361: 1347-8
50. Updated "yellow card" launched. Pharm J 2000; 265: 387
51. Gogolak VV. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see. Pharmacoepidemiol Drug Saf 2003; 12: 249-52
52. Medicines Control Agency. Consultation MLX 286: proposals to prohibit the herbal ingredient kava-kava (Piper methysticum) in unlicensed medicines. London: Medicines Control Agency, 2002 Jul 19
53. The Medicines for Human Use (Kava-Kava) (Prohibition) Order 2002 (S12002/3170). London: The Stationery Office, 2003
54. Van Grootheest K, de Graaf L, de Jong-van den Gerg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26 (4): 211-7
55. Wingfield J, Walmsley J, Norman C. What do Boots pharmacists know about yellow card reporting of adverse drug reactions? Pharm J 2002; 269: 109-10
56. Green CF, Mottram DR, Raval D, et al. Community pharmacists' attitudes to adverse drug reaction reporting. Int J Pharm Prac 1999; 7: 92-9
57. Biscoe R, Houghton JE, Woods FJ. An audit of the level of encouragement given by medicines information pharmacists to enquirers of suspected adverse drug reactions to complete a yellow card report: perspectives in patient safety [abstract]. 28th UK Medicines information Conference Proceedings; 2002 Sep 19-21; Chester, UK
58. Pharmacists' adverse drug reaction reporting to start on April 1. Pharm J 1997; 258: 330-1
59. Cox A. Embracing ADR reporting could improve pharmacists' standing [letter]. Pharm J 2002; 269: 14
60. Moffat T. Adverse drug reaction (ADR) reporting by pharmacists. London: Royal Pharmaceutical Society of Great Britain, 2003. In press
61. Farah MH, Edwards R, Lindquist M, et al. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf 2000; 9: 105-12
62. World Health Organisation Collaborating Centre for International Drug Monitoring. Draft guidelines for herbal ATC classification. Uppsala: The Uppsala Monitoring Centre, 2002
63. Broughton A. Yellow card reporting scheme. Eur J Herb Med 2001; Dec: 3-6
64. Ward T. Register for Chinese Medical Herbalists. 2002 Sep 18
65. European Scientific Co-operative on Phytotherapy (ESCOP). PhytoNET [online]. Available from URL: http://www.es-cop.com [Accessed 2003 Jul 29]
66. British Herbal Medicine Association. Code of good practice: unlicensed herbal remedies. Bournemouth: British Herbal Medicine Association, 1997 Mar
67. Nutraceuticals adverse events database. Executive summary [online]. Available from URL: http://www.wmin.ac.uk/sih/research/proj_nutraceuticals.html [Accessed 2003 Jul 25]
68. Logue M, Pendry B, Waters E, et al. Irritable bowel syndrome: herbal research update [abstract]. Phytotherapy Research Conference; 2002 Apr, Glasgow
69. Shakir SAW. PEM in the UK. In: Mann RD, Andrews EB, editors. Pharmacovigilance, Chicester: Wiley, 2002: 333-44
70. Layton D, Sinclair HK, Bond CM, et al. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002; 11: 503-13
71. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-the-counter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Saf 1999; 8: 479-91
72. Strom BL. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chicester: Wiley, 2000: 401-13
73. Berry DC, Knapp PR, Raynor DK. Is 15% very common: informing people about the risks of medication side effects. Int J Pharm Prac 2002; 10: 145-51
74. Berry DC, Raynor DK, Knapp P, et al. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 2003; 26(1): 1-11
75. Edwards IR, Olsson S. WHO programme: global monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. Chicester: Wiley, 2002: 169-82
76. Cosyns J-P. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 2003; 26 (1): 33-48
77. Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56
78. Kava-kava and hepatotoxicity [news item]. Curr Prob Pharmacovigilance 2002; 28: 6
79. House of Lords Select Committee on Science and Technology, Session 1999-2000, 6th report. Complementary and alternative medicine. London: The Stationery Office, 2000
80. Department of Health. A vision for pharmacy in the new NHS. London: Department of Health. 2003 Jul
81. Pirmohamed M, Park BK. Genetic susceptibility to ADRs. Trends Pharmacol Sci 2001; 22 (6): 298-305